Latest news

Keeping rheumatoid arthritis in check – start early to save your joints

New information and resources for consumers about the rheumatoid arthritis journey – from diagnosis to treatment – have been released by the Targeted Therapies Alliance, of which Arthritis Australia is a member. Resources include a consumer video about living with methotrexate in addition to a series of patient ‘roadmaps’, action plans and decision-making aids which…

New CEO appointed for Arthritis Australia

The Board of Arthritis Australia is pleased to announce the appointment of Jonathan Smithers as our new Chief Executive Officer Chair of the Board, Kristine Riethmiller said, “I know I speak for the entire Board when I say we are excited to have secured the services of an outstanding candidate. Jonathan brings a wealth of…


Reducing opioid harm through regulatory changes – Information for consumers, patients and carers

The Australian Government, through the Therapeutic Goods Administration (TGA) within the Department of Health, is implementing a number of regulatory changes in order to minimise the harms caused by opioid prescription medicines to Australians each year. The changes will ensure the safe and effective prescribing and use of opioids while maintaining access for patients who…

Arthritis Australia launches ground-breaking Rheumatoid Arthritis patient-support website

Arthritis Australia, in partnership with the Australian Rheumatology Association, has launched a new online rheumatoid arthritis patient-support website. The free MyRA website provides individually tailored information designed to help people seize control and become active participants in their journey with the disease.

PIDA Accessible Packaging Design Special Award 2019

Ecolean received the GOLD award for the Accessible Packaging Design Special Award 2020. Congratulations to Ecolean for their innovative flexible pouch, and to Bannister Downs Dairy for being industry leaders in utilising this type of packaging for their products. The pouch design is lightweight, easy to grip and stable to pour. It features also features…


UPDATED: Advice regarding Coronavirus (Covid-19) from the Australian Rheumatology Association

Due to the increasing number of infections in Australia from Coronavirus (Covid-19), we are aware of growing concerns raised by patients with chronic illnesses and medications that affect their immune system. Currently, there is no specific advice for immune- compromised patients.

Australian Rheumatology Association and Arthritis Australia Statement regarding the use of glucosamine for the treatment of Osteoarthritis

Recent media reports have raised concern over the use of glucosamine in the treatment of osteoarthritis.  These reports appear to be based on two unrelated recent events:   A change in recommendation by the American College of Rheumatology (ACR) [1] In October 2019 the ACR updated their guidelines for the management of osteoarthritis from a…

New campaign reveals blind spot for older Australians

Arthritis Australia is urging older Australians to look out for symptoms of silent inflammation that could put their eyesight at risk, and to speak to their doctor without delay. More than a thousand Australians over 50 years old are affected each year by Giant Cell Arteritis, an autoimmune disease where the body mistakenly attacks its…


Arthritis Australia launches new Multicultural Resources

Non-English-speaking communities will have improved access to information about arthritis and its management with the launch today of a new series of arthritis information sheets in fourteen different languages.

A new approach to support specialist prescribing of bDMARDs

Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the  successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant. The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies. NPS…